NovaGo Therapeutics
NovaGo Therapeutics Raises $30M Series B for Spinal Cord Injury Study
NovaGo Therapeutics announced $30M in Series B financing on September 2, 2026. NovaGo Therapeutics raised a $30 million Series B led by Neurimmune and Pureos Bioventures to advance a proof-of-concept study in acute spinal cord injury.
Round details
The financing includes backing from Neurimmune, Pureos Bioventures. The company did not publish a valuation with the announcement.
- Round: Series B
- Capital announced: $30M
- Headquarters: Schlieren, Switzerland
How the company plans to use the capital
NovaGo will use the proceeds to advance its lead program into a proof-of-concept study in patients with acute spinal cord injury, a randomized, double-blind trial enrolling 120 patients across sites in Germany, Spain, and Switzerland. The equity round was complemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life.
Why this matters for GTM teams
The round moves an anti-Nogo-A biologic from a Phase 1 study toward a randomized, double-blind proof-of-concept study in acute spinal cord injury, with existing and new investors participating alongside the two lead investors.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: NovaGo Therapeutics Series B announcement.
Company Info
Investors (2)
Share
Related Reports
Armadin Raises $255.5M Series B for Autonomous Security
Armadin raised a $255.5 million Series B co-led by Andreessen Horowitz and Accel to scale its agentic security platform and its research, training, and go-to-market efforts.
Homeward Raises $120M Series D for Cash Offer and Bridge Financing
Homeward raised a $120 million Series D led by Saluda Grade, plus $330 million in asset-backed debt, to expand cash offer and bridge financing for real estate agents.
Varda Raises $251M Series D for Space-Based Pharmaceutical Processing
Varda Space Industries raised a $251 million Series D led by Lux Capital and Natural Capital to scale space-based pharmaceutical processing.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free